Cervical Cancer Treatment Market

Cervical Cancer Treatment Market Outlook 2031

The global cervical cancer treatment market size was USD 8.44 Billion in 2022 and is anticipated to reach USD 13.09 Billion by 2031 expand at a substantial CAGR 5% during the forecast period, 2023–2031. The growth of the market is attributed to the increasing prevalence of cervical cancer, favorable government initiatives and introduction of targeted treatments.

Cervical cancer is a kind of cancer that develops in the cervix. The cervix is a hollow cylinder that links a woman's uterus to her vaginal canal. The majority of cervical cancers start in cells on the cervix's surface. Cervical cancer used to be a significant cause of mortality among women in the US. Since screening tests become widely available, this has improved

Get Free Sample Report

Many women with cervical cancer are unaware that they have it until it has progressed to the point where symptoms appear. When symptoms do appear, they are frequently misinterpreted as menstrual cycles or urinary tract infections (UTIs). Unusual bleeding, such as between periods, after sex, or after menopause, vaginal discharge that looks or smells different than usual, pain in the pelvis, a need to urinate more frequently, and pain while urination are all common cervical cancer symptoms.

The sexually transmitted human papillomavirus (HPV) is responsible for the majority of cervical cancer cases. The virus that causes genital warts is the same one that causes this. There are over 100 distinct HPV strains. Cervical cancer is caused by just a few kinds. HPV-16 and HPV-18 are the two most prevalent kinds that cause cancer.

Cervical cancer is not inevitable if you are infected with a cancer-causing strain of HPV. The vast majority of HPV infections are cleared by your immune system within two years. Doctors use a Pap smear test to diagnose cervical cancer. To do this test, the doctor takes a sample of cells from the patient's cervix's surface.

These cells are then submitted to a lab for precancerous or cancerous changes to be examined for. If these changes are identified, the doctor may recommend a colposcopy, which is a technique for checking the cervix of the patient. A biopsy, which is a sample of cervical cells, may be taken during this examination. After a cancer diagnosis, the doctor will give a stage to the patient's cancer.

The stage indicates whether or not the cancer has spread and, if so, how far it has spread. Patients' cancer is staged to help doctors select the best treatment for them. Cervical cancer can be successfully treated if detected early. Surgery, radiation therapy, chemotherapy, and targeted therapy are the four primary therapies. These therapies are sometimes combined to improve their efficacy.

Human immunodeficiency virus (HIV), chlamydia, smoking, obesity, a family history of cervical cancer, a low-fiber diet, using birth control pills, having three full-term pregnancies, and being younger than 17 when you got pregnant for the first time are all risk factors for developing cervical cancer.

Cervical Cancer Treatment Market Trends, Drivers, Restraints, and Opportunities

• Increasing prevalence of human immunodeficiency virus in women is projected to boost the market growth during the forecast period.
• Increasing demand for early diagnosis and treatment of cervical cancer are anticipated to drive the market growth in the coming years.
• Technological advancements of targeted therapies and favorable government initiatives are estimated to fuel the market growth.
• Lack of awareness, adverse effects associated with cancer therapy and other misconceptions about cervical cancers is projected to hamper the market growth during the forecast period.
• High cost of treatment is anticipated to hinder the market growth during the forecast period.
• Increased R&D investment in oncologic diseases segment is expected to offer lucrative opportunities for the market players.

Scope of The Cervical Cancer Treatment Market Report

The report on the global cervical cancer treatment market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Cervical Cancer Treatment Market Segment Insights

Squamous cell carcinoma segment is expected to account for a key share

Based on types, the cervical cancer treatment market is segmented into squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma. The squamous cell carcinoma segment is expected to account for a key share of the market during the forecast period owing to its increased prevalence. If left untreated, high-grade squamous intraepithelial lesion (HSIL) of the cervix can develop to squamous cell carcinoma (SCC).

Screening using Pap tests on a regular basis aids in the early detection and diagnosis of SCC. Adenocarcinoma of the cervix is more common in certain ethnic groups, such as Hispanic and African-American women. The histology, as seen under a microscope, is used to distinguish between SCC and adenocarcinoma. Cervical adenosquamous carcinoma is the most uncommon form, affecting both squamous and glandular tissues.

Get Free Sample Report

Gardasil segment is expected to hold a key share

Based on product, the cervical cancer treatment market is bifurcated into prevention, and treatment. The prevention segment is further sub segmented into gardasil/gardasil 9 and cervarix. The treatment segment is further sub segmented into avastin, keytruda, generics, and others. The gardasil segment is expected to hold a key share of the market during the forecast period owing to increased sales around the world.

In addition, the FDA authorized Gardasil 9 in 2015, which is a modified, nonavalent form of Gardasil. Gardasil (quadrivalent) and Gardasil 9 (nonavalent) gained a significant clinical advantage over Cervarix as a result of this label extension (bivalent). Cervarix was withdrawn from the US market by GlaxoSmithKline in 2016 owing to poor demand and fierce competition.

Although generic medicines continue to dominate the market, biologics and other targeted treatments are expected to bring in a paradigm change in this therapeutic area during the forecast period.

Hospital pharmacies segment is expected to constitute a key share

Based on distribution channel, the cervical cancer treatment market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is expected to constitute a key share of the market during the forecast period owing to increasing consumer awareness and increased healthcare expenditure. Cervical cancer products are kept in stock at hospital pharmacies for both out-patients and in-patients.

On the other hand, the online pharmacies segment is anticipated to expand at a rapid pace during the forecast period owing to its convenience offered in terms of price, access and delivery and the user-friendly interface. Furthermore, they provide a variety of discounts for purchases above a specific amount, as well as bundle prices for cancer products.

Get Free Sample Report

North America is anticipated to dominate the market

On the basis of regions, the Cervical Cancer Treatment market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market during the forecast period. The regional market growth can be attributed to increasing cancer prevalence, increased consumer awareness, and technological advancements in the diagnosis and treatment of oncological diseases.

The regional market is being driven by an increase in the number of health initiatives undertaken by private and public sector organizations, as well as the use of more advanced technology.

On the other hand, Asia Pacific is expected to exhibit a rapid growth rate in the coming years due to growing population, increasing disease prevalence, and demand for cost-effective treatments. Biosimilars' growing popularity in emerging countries like India and China might change the therapeutic landscape in the region.

Get Free Sample Report

Segments

Types

• Squamous Cell Carcinoma (SCC)
• Adenocarcinoma
• Adenosquamous Carcinoma

Products

• Prevention
  • Gardasil/Gardasil9
  • Cervarix
• Treatment
  • Avastin
  • Keytruda
  • Generics
  • Others

Distribution Channels

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• F. Hoffmann-LA Roche AG
• Merck & Co., Inc.
• GlaxoSmithKline PLC
• Allergan PLC
• Pfizer, Inc.
• Biocon Ltd.
• Bristol-Myers Squibb
• AstraZeneca PLC
• Eli Lilly & Co. Merck & Co.

Competitive Landscape

Key players competing in the Cervical Cancer Treatment market are F. Hoffmann-LA Roche AG; Merck & Co., Inc.; GlaxoSmithKline PLC; Allergan PLC; Pfizer, Inc.; Biocon Ltd.; Bristol-Myers Squibb; AstraZeneca PLC; and Eli Lilly & Co. Merck & Co.

Some of the key business strategies employed by companies includes mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase their market shares. For example, in January 2019, Celgene was acquired for $74 billion by Bristol-Myers Squibb, an American biopharmaceutical firm. With this acquisition, Bristol-Myers Squibb will be able to maintain a strong presence in the cancer, immunology, inflammatory, and cardiovascular disorders medication markets.